Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | MGAM | O43451 | 3/20 | 0.43 |
| ▸ | SI | P14410 | 3/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | COASY | Q13057 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10397230 | 0.86 | PDE10A (0.57) | GRIN1GRIN2BDDAH1PDE10ACHEK1 | |
| SCHEMBL9533100 | 0.84 | GRIN1 (0.55) | GRIN1GRIN2BPDE10ACHEK1GAA | |
| SCHEMBL3245583 | 0.83 | PDE10A (0.54) | GRIN1GRIN2BPDE10APARP1ALDH1A1 | |
| SCHEMBL4066021 | 0.82 | GRIN1 (0.54) | GRIN1GRIN2BPDE10ACHEK1GAA | |
| SCHEMBL16523722 | 0.81 | GRIN1 (0.52) | GRIN1GRIN2BPDE10ACHEK1GAA | |
| SCHEMBL4919548 | 0.80 | DDAH1 (0.55) | DDAH1GAAMGAMSIMGAM2 | |
| SCHEMBL2899660 | 0.80 | DDAH1 (0.55) | DDAH1CHEK1GAAADORA3ADORA2A | |
| SCHEMBL30518181 | 0.80 | DDAH1 (0.55) | DDAH1GAAMGAMSIMGAM2 | |
| SCHEMBL1918622 | 0.79 | DDAH1 (0.53) | DDAH1CHEK1GAAMGAMSI | |
| SCHEMBL17308357 | 0.79 | DDAH1 (0.53) | DDAH1CHEK1GAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012024419-A2 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | GRIN1 875/4885GRIN2B 769/4885DDAH1 1125/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | GRIN1 875/4885GRIN2B 769/4885DDAH1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.